Agios Pharmaceuticals
AGIO
185 hedge funds and large institutions have $3.63B invested in Agios Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 62 reducing their positions, and 27 closing their positions.
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
13.32% more ownership
Funds ownership: 93.76% → 107.08% (+13%)
8% more capital invested
Capital invested by funds: $3.37B → $3.63B (+$264M)
6% more funds holding
Funds holding: 174 → 185 (+11)
11% less call options, than puts
Call options by funds: $27.3M | Put options by funds: $30.7M
19% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 62
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$100M |
| 2 |
BlackRock
New York
|
+$72.4M |
| 3 |
Goldman Sachs
New York
|
+$32M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$18.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$79.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$37.3M |
| 3 |
N
Natixis
Paris,
France
|
-$24M |
| 4 |
Millennium Management
New York
|
-$12.1M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$10.3M |
AGIO Hedge Fund Activity: Q2 2021 in Review
185 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2021, worth a combined $3.63B — up 7.8% from $3.37B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new AGIO positions and 27 closed out — a net gain of 12 holders — while 50 added to existing stakes and 62 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $100M. The largest seller was HealthCor Management, exiting entirely with an estimated $79.2M sold.
- 185 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2021, up from 174 in Q1 2021.
- Funds reported $3.63B of Agios Pharmaceuticals stock for Q2 2021, up 7.8% quarter-over-quarter.
- 39 funds opened new Agios Pharmaceuticals positions in Q2 2021 and 27 closed out, a net change of +12 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2021 was JP Morgan Chase, an estimated $100M added.
- The largest Agios Pharmaceuticals seller in Q2 2021 was HealthCor Management, an estimated $79.2M sold.
Based on aggregated 13F filings for Q2 2021.